Published in
American Society of Hematology, Blood, 8(126), p. 1009-1016, 2015
DOI: 10.1182/blood-2014-12-614743
Links
Tools
Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
Journal article published in 2015 by
Stéphane Barete 
,
Olivier Lortholary,
Gandhi Damaj,
Isabelle Hirsch,
Marie Olivia Chandesris,
Caroline Elie,
Mohamed Hamidou,
Isabelle Durieu,
Felipe Suarez,
Bernard Grosbois,
Nicolas Limal,
Emmanuel Gyan,
Claire Larroche,
Gérard Guillet,
Jean Emmanuel Kahn
and other authors.
,
Olivier Lortholary,
Gandhi Damaj,
Isabelle Hirsch,
Marie Olivia Chandesris,
Caroline Elie,
Mohamed Hamidou,
Isabelle Durieu,
Felipe Suarez,
Bernard Grosbois,
Nicolas Limal,
Emmanuel Gyan,
Claire Larroche,
Gérard Guillet,
Jean Emmanuel Kahn
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points 2-CdA is an effective treatment with a long-term acceptable safety profile in patients with mastocytosis. 2-CdA is effective and safe in indolent systemic mastocytosis and cutaneous mastocytosis refractory to multiple symptomatic therapies.